SCHEMBL29580475

SCHEMBL29580475

C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ OPRL1 P41146 3/20 0.45
▸ CXCR4 P61073 2/20 0.44
▸ TFPI P10646 1/20 0.41
▸ NPY5R Q15761 3/20 0.40
▸ NPY1R P25929 2/20 0.40
▸ NPY4R P50391 2/20 0.40
▸ EPHA2 P29317 1/20 0.40
▸ RAMP3 O60896 3/20 0.40
▸ CALCR P30988 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2068782 0.93 GNPAT (0.40) OPRL1CXCR4NPY5RNPY1RNPY4R
SCHEMBL31232972 0.92 NPY5R (0.47) CXCR4TFPINPY5RNPY1RNPY4R
SCHEMBL5849482 0.91 OPRL1 (0.40) OPRL1CXCR4TFPINPY5RNPY1R
SCHEMBL5849470 0.91 OPRL1 (0.40) OPRL1CXCR4TFPINPY5RNPY1R
SCHEMBL31031533 0.89 OPRL1 (0.41) OPRL1CXCR4NPY5RNPY1RNPY4R
SCHEMBL29371979 0.88 TFPI (0.42) OPRL1TFPINPY5RNPY1RNPY4R
SCHEMBL31303211 0.88 NPY4R (0.48) NPY5RNPY1RNPY4R
SCHEMBL29880860 0.88 GNPAT (0.41) NPY5RNPY1RNPY4R
SCHEMBL29542608 0.87 TFPI (0.44) OPRL1CXCR4TFPIRAMP3CALCR
SCHEMBL31370850 0.87 OPRL1 (0.44) OPRL1CXCR4NPY5RNPY1RNPY4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114426582-B Nerve specific enolase monoclonal antibody and preparation method and application thereof 陕西脉元生物科技有限公司 2022-11-25 — — CN disclosed
CN-114426582-A Nerve specific enolase monoclonal antibody and preparation method and application thereof 陕西脉元生物科技有限公司 2022-05-03 — — CN disclosed
Send feedback